Schrödinger’s Q1 2026: A Hosted Licensing Pivot, Bunsen in the Wings, and a Pharma Validation

Overview: a quarter of reclassification and transition bets

Schrödinger, Inc. (Nasdaq: SDGR) reported results for the quarter ended March 31, 2026, painting a picture of a company steering its revenue mix toward hosted software and away from traditional software licenses. Total revenue came to $58.6 million, down 2% from a year ago, while ACV rose to $28.4 million—a 12% year-over-year increase. On a trailing four-quarter basis, ACV stood at $201 million, suggesting a solid, if not spectacular, pipeline continuation.

Within the mix, software revenue was $35.6 million, a 21% decline as the company accelerates its transition to hosted software licensing. Drug discovery revenue rose to $22.9 million, aided by the accelerated recognition of deferred revenue and the winding down of at least one collaboration program. Contribution revenue was minimal at $0.1 million, compared with $4.3 million a year prior, reflecting the completion of a predictive toxicology grant. Total revenue’s slight dip mirrors this deliberate shift in revenue categorization and timing.

From a profitability lens, software gross margins remained robust at 69%, but operating expenses totaled $78.3 million, a 4% decline from the prior period. Other expenses, largely driven by changes in the fair value of equity investments and interest income/expense, were $10.8 million. Net loss widened modestly to $60.0 million from $59.8 million a year earlier. Notably, cash, cash equivalents, restricted cash and marketable securities were $406 million at the end of the quarter, providing a meaningful runway as the company funds its growth initiatives.

Revenue mix and disclosure shifts

Schrödinger now presents contribution revenue and cost of revenue separately from software and drug discovery revenue and cost. The company indicates that prior periods have been reclassified to conform to this presentation in order to facilitate year-over-year comparability. The change underscores a broader strategy: highlight recurring, contribution-style revenue while continuing to monetize the core software and drug discovery offerings. For readers focused on earnings metrics like EPS and EPS consensus, this reclassification can introduce a short-term pruning of familiar baselines, complicating quick comparisons until the new structure becomes standard in the model.

Bunsen, the agentic AI co-scientist, and the hosted licensing narrative

Two headline features anchor Schrödinger’s forward-looking story. First, the company reiterated expectations around Bunsen, described as an agentic AI co-scientist intended to autonomously execute complex molecular discovery workflows. The aim is to expand utilization to a broader user base and accelerate value capture from the computational platform that blends ground-truth simulation with AI. Second, the ongoing transition to hosted software licensing signals a strategic shift toward recurring revenue and higher long-run visibility, even if near-term revenue mix softness persists in software revenues.

Outlook and sector implications

As of May 5, 2026, Schrödinger maintained its previously issued financial guidance for the fiscal year ending December 31, 2026. While the exact figures were not re-stated in the released snippet, the commitment to guidance suggests management confidence in the hosted licensing trajectory and its impact on annual revenue cadence and operating leverage.

For the broader biotech-NLP interface and AI-enabled drug discovery space, Schrödinger’s Q1 narrative reinforces a few themes. One, the hosted licensing model remains a work in progress for many tech-enabled pharma players—potentially offering steadier cash flows but presenting near-term headwinds as customers shift from upfront software purchases to subscription-based structures. Two, the AI co-scientist concept, if delivered as promised, could become a differentiator in how quickly teams move from concept to candidate. Three, corporate transactions around platform ecosystems—evidenced by Lilly’s $2.3 billion Ajax Therapeutics acquisition and Schrödinger’s equity stake in the deal—signal industry validation for partner-led value creation. A six percent equity stake is not large enough to move the dial by itself, but it’s a signal that Schrödinger’s technology or its co-discovery approach sits in a coveted tier of strategic importance for large pharmas.

Takeaways: a model in motion, not a moment of rest

The quarter reads like a memo from a company recalibrating its business model while trying to preserve optionality. The 12% ACV gain, the drag from software transition, and the drag-and-pull between current revenue recognition and future hosted licensing all factor into a longer-term story rather than a single quarter’s result. Investors watching for EPS and EPS consensus should note the absence of explicit per-share data in the press release; the real test for the stock may hinge on whether Schrödinger can translate higher recurring revenue visibility into durable profitability—an achievement that would likely widen the gap between reported revenue and the market’s revenue forecast expectations for the year ahead.

In the near term, the sector peers will watch how Schrödinger uses cash on hand to fund platform enhancements and how Bunsen’s rollout translates into realized downstream value. The Ajax tranche under Lilly’s umbrella provides a real-world case study of co-discovery synergies and the strategic premium large biopharmas are willing to pay for access to computational platforms that accelerate discovery timelines. If Schrödinger can pair the platform upside with a clearer path to profitability, the conversation around SAAS-like growth in biotech tools could move from novelty to necessity.